ClinicalTrials.gg
TerminatedNCT04425070TOUCHUpdated Jan 5, 2026

A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma

A Phase 1/2 interventional study of ICE [ifosfamide+carboplatin+etoposide] and GEMOX [gemcitabine+oxaliplatin] in Peripheral T-cell Lymphoma and NK/T-cell Lymphoma, sponsored by Antengene Corporation. Terminated at 13 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Antengene Corporation · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Based on the adjustment of clinical research and development strategy,sponsor decided to terminate the study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Lymphoma, T-Cell, Peripheral with a site in China — 64 open to participants now, 70 under way, 10 of them phase 3. Lymphoma, T-Cell, Peripheral · China.

Enrollment
49th of 106
56 · median 50
Started
2020
with 14 others
Phase 1/2
25 of 114
18 open now
Registered
31st of 114
by date

Among the 114 studies in Lymphoma, T-Cell, Peripheral with a site in China, this one is the 49th largest by enrollment of the 106 interventional ones that give a count, is one of 15 that started in 2020, is one of 25 in phase 1/2, and was the 31st registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

64 of the 114 studies in Lymphoma, T-Cell, Peripheral with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lymphoma, T-Cell, Peripheral with a site in China, or all of them as a file.
02

Study summary

This trial is proposed with treatment of ATG-010 combined with chemotherapy regimens which will be chosen by investigators (ICE [ifosfamide+carboplatin+etoposide] or GEMOX [gemcitabine+oxaliplatin] or Tislelizumab), after treatments of 2 to 6 cycles transferring to ATG-010 monotherapy maintenance treatment, to evaluate the safety, tolerability, and primary efficacy of ATG-010 in R/R PTCL and NK/T-cell lymphoma patients.

Read the detailed description

This trial is an open-label, multi-center Phase Ib clinical study that will evaluate ATG-010 combined with chemotherapy regimen selected by investigators (ICE regimen ifosfamide+carboplatin+etoposide; Or GEMOX regimen: gemcitabine+oxaliplatin; Tislelizumab) sequential ATG 010 monotherapy maintenance, to evaluate the safety, tolerability, and primary efficacy in R/R PTCL and NK/T-cell lymphoma patients. 97 patients are planned to be enrolled.

03

Conditions studied

  • Peripheral T-cell Lymphoma
  • NK/T-cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient is willing to provide written ICF.
  2. Age≥ 18 years.
  3. R/R PTCL and NK/T-cell lymphoma as confirmed by histological methods according to WHO classification of tumors of lymphoid tissues 2016.
  4. Previously received at least one or more standard regimens including anthracycline.
  5. Recurrence or the recurrence disease after the last treatment completed.
  6. At least one per modified efficacy assessment criteria (Cheson 2014).
  7. PS 0 or 1.
  8. Any toxicity caused by previously anti-tumor therapy must recovered to ≤ Grade 1 ( v5.0) with exception of hearing loss, alopecia, and pigmentation.
  9. Expected life time longer than 3 months.

Exclusion criteria

Exclusion Criteria:

  1. Current have disease or history of central nervous system lymphoma.
  2. positive, or positive.
  3. Patients with a known history of (HIV) infection and/or acquired immunodeficiency syndrome.
  4. Received major surgery within 4 weeks of first dose of study drug
  5. Known received SINE, including ATG-010.
  6. Unable to swallow the tablets, suffers from malabsorption syndrome, or any other gastrointestinal disease or dysfunction that may interfere with ATG-010 absorption.
  7. Known allergy to ATG-010, or ICE, or GEMOX.
  8. A woman who is pregnant or nursing.
  9. The investigator considerations on patient's complications or other conditions may affect protocol compliance or may be inappropriate for participation in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    ATG-010 + ICE

    ATG-010 60 mg/once,total twice in each cycle; on Days 4 and 11

    Combination Product: ICE [ifosfamide+carboplatin+etoposide]

  • Experimental
    ATG-010 + GEMOX

    ATG-010 60 mg/once,total twice in each cycle; on Days 2 and 9

    Combination Product: GEMOX [gemcitabine+oxaliplatin]

  • Experimental
    ATG-010 + Tislelizumab

    ATG 010 40mg/once, will be given on Days 1, 8, and 15 of each cycle

    Combination Product: Tislelizumab

Interventions

  • Combination productICE [ifosfamide+carboplatin+etoposide]

    • Combined with ICE chemotherapy regimen: * Ifosfamide: 5 g/m2, continuous intravenous (iv) infusion (mesna 5 g/m2 synchronously iv infusion for rescue), on Day 2; * Carboplatin: with concentration-area under time curve (AUC)=5 (highest concentration to 800 mg), iv infusion, on Day 2; * Etoposide l00 mg/m2, iv infusion, on Days 1-3; * ATG-010 60 mg/once, oral, on Days 4 and 11. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW).

  • Combination productGEMOX [gemcitabine+oxaliplatin]

    Drug page: Gemcitabine-oxaliplatin regimen

    • Combined with GEMOX chemotherapy regimen: * Gemcitabine 1000 mg/m2, iv infusion, on Days 1 and 8; * Oxaliplatin 130 mg/m2, iv infusion, on Day 1; * ATG-010 60 mg/once, oral, on Days 2 and 9. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW).

  • Combination productTislelizumab

    Tislelizumab will be administered intravenously at a fixed dose of 2 0 0 mg every 3 weeks on Day 1 of each cycle

06

What researchers measure

Primary outcomes

  1. AEs/SAEs

    Toxicity will be graded according to the NCI CTCAE, Version 5.0.

    Time frame: 18 months

  2. Overall Response Rate (ORR)

    To determine the overall response rate according to Chenson 2014.

    Time frame: 18 months

Secondary outcomes

  1. Duration of response (DOR)

    Duration of time from first occurrence of CR or PR until the first date that disease progression is objectively documented.

    Time frame: 18 months

  2. Disease control rate (DCR)

    Proportion of patients who achieve CR, PR, or SD for a minimum of 4 weeks, following the first dose of study drug (i.e., CR+PR+SD)

    Time frame: 4 weeks to 18 months

  3. Progression-free survival (PFS)

    Duration of time from the first dose of study drug until progression or death due to any cause

    Time frame: 18 months

  4. Overall Survival (OS)

    Duration of time from the first dose of study drug until death due to any cause

    Time frame: 18 months

07

Study locations

13 sites
  • Anhui Provincial Cancer Hospital
    Hefei, Anhui 230031, China
  • Beijing Tongren Hospital.CMU
    Beijing, Beijing Municipality 100005, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing Municipality 400030, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Guangxi Medical University Cancer Hospital
    Nanning, Guangxi 530021, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu 210000, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200032, China
  • Tianjin Medical Universisity Cancer Institute & Hospital
    Tianjin, Tianjin Municipality 300060, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
08

References and documents

Publications

  • Liu C, Li D, Gao Y, Zhang W, Guo Z, Zhao J, Huang H, Tao R. Selinexor plus tislelizumab in patients with relapsed/refractory NK/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial. Oncologist. 2026 Jul 11:oyag266. doi: 10.1093/oncolo/oyag266. Online ahead of print. PubMed 42438166 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Dec 2025, 64 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2020
First posted
Jun 11, 2020
StartActual
Aug 18, 2020
Primary completionActual
Dec 30, 2025
CompletionActual
Dec 30, 2025
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04425070
Lead sponsor
Antengene Corporation
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Aug 18, 2020
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025
Last update
Jan 5, 2026

Study contacts

Yang Yu, MD
study director · Medical Director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine-oxaliplatin regimen · Tislelizumab

Start the discussion